Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $24.33.

CNCE has been the subject of a number of research analyst reports. ValuEngine downgraded Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 23rd. BidaskClub raised Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 30th. Janney Montgomery Scott initiated coverage on Concert Pharmaceuticals in a research report on Thursday, September 13th. They set a “neutral” rating for the company. Zacks Investment Research downgraded Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. Finally, UBS Group set a $19.00 target price on Concert Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 13th.

In other news, Director Richard Aldrich bought 50,000 shares of the firm’s stock in a transaction on Thursday, November 15th. The stock was acquired at an average cost of $11.83 per share, with a total value of $591,500.00. Following the completion of the transaction, the director now directly owns 296,975 shares of the company’s stock, valued at approximately $3,513,214.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. increased its position in Concert Pharmaceuticals by 679.4% in the second quarter. Meeder Asset Management Inc. now owns 6,305 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,496 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Concert Pharmaceuticals in the second quarter worth $178,000. Mackenzie Financial Corp bought a new position in shares of Concert Pharmaceuticals in the third quarter worth $160,000. Jefferies Group LLC bought a new position in shares of Concert Pharmaceuticals in the third quarter worth $174,000. Finally, Cambria Investment Management L.P. bought a new position in shares of Concert Pharmaceuticals in the second quarter worth $216,000. 73.31% of the stock is owned by institutional investors and hedge funds.

Shares of CNCE traded up $0.05 on Friday, reaching $12.52. 308,856 shares of the company’s stock traded hands, compared to its average volume of 242,647. The company has a market capitalization of $295.68 million, a price-to-earnings ratio of 3.07 and a beta of 0.87. Concert Pharmaceuticals has a 52-week low of $10.80 and a 52-week high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.12). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.02 million. Concert Pharmaceuticals had a negative net margin of 392.62% and a negative return on equity of 20.81%. Sell-side analysts anticipate that Concert Pharmaceuticals will post -2.25 EPS for the current year.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Article: How to calculate the annual rate of depreciation

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.